University of California Davis Comprehensive Cancer Center

Sacramento, CA
Website
(888) 803-1766

Sorting 4 by

Accepting patients

KT-253

A Phase 1, Multicenter, Open-Label, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Intravenously Administered KT-253 in Adult Patients With High Grade Myeloid Malignancies and Acute Lymphocytic Leukemia, Lymphoma and Advanced Solid Tumors
Learn more
  • MDM2 Inhibitor
  • Phase 1

Accepting patients

Venetoclax in Combination With ASTX727

Venetoclax in Combination With ASTX727, an All-ORal Therapy for Chronic Myelomonocytic Leukemia and Other MDS/MPN With Excess Blasts (VICTORY-MDS/MPN): A Randomized, Phase 2 Trial
Learn more
  • BCL-2 Inhibitor
  • Hypomethylating Agents (HMA)
  • Phase 2
Get personalized results in 60 seconds
All clinical trials have eligibility criteria - or a list of reasons why you may be able or unable to participate in a trial. Answer a few questions to view your personalized results - all in under 60 seconds.
Help me find trials

Accepting patients

TWT-202

Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine or Decitabine in Patients With AML, MDS or CMML
Learn more
  • Hypomethylating Agents (HMA)
  • PLK4 Inhibitor
  • Phase 1/2
  • Has results

Accepting patients

A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
Learn more
  • Allogeneic Stem Cell Transplant
  • Phase 1